Phillip Taboada/X
Aug 26, 2025, 09:56
Phillip Taboada: TXA Shows No Added Benefit in Aquablation
Phillip Taboada, MS4 at UT Southwestern Medical Center and urology applicant, posted on X:
”New work in New work in Canadian J Urology.
Limited TUR during Aquablation provides adequate hemostasis. TXA offered no clear benefit in reducing hematuria or transfusions.
Thanks UT Southwestern Urology for the support!”
Read the full article here.
Title: Tranexamic acid and hematuria outcomes following aquablation for benign prostatic hyperplasia
Authors: Phillip Taboada, Rohit R. Badia, Dhillon Advano, Andrew Murphy, Christina Sze, Ryan J. Mauck, Jennifer Tse, Jeffrey Gahan, Claus G. Roehrborn, Ramy Goueli
Stay updated on the latest scientific advancements with Hemostasis Today.
-
May 31, 2026, 16:29José Antonio García Erce: Collaborative PBM Implementation in Transfusion Centers and Services
-
May 31, 2026, 16:22Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
-
May 31, 2026, 16:21Ksenija Stach: Is This The Future of Lipid-Lowering Lherapy?
-
May 31, 2026, 15:42Antonio Greco: Balancing Bleeding and Thrombotic Risk After PCI
-
May 31, 2026, 15:41Eric Topol: Replication of Plasma p-tau217 Blood Test for Predicting Alzheimer’s Disease
-
May 31, 2026, 15:32ASH Invites Dynamic Members to Apply for 2027 Leadership and Committee Roles
-
May 31, 2026, 14:39Monique Gore-Massy: Redefining Lupus Innovation Through Patient Partnership
-
May 31, 2026, 14:31Mirjam Teboe: The Golden Rule Behind Reliable Lupus Anticoagulant Testing
-
May 31, 2026, 14:20Improving Access to Care for People Living with Haemophilia and Haemoglobinopathies – NNHF